These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 27576942)

  • 1. Calcium as a cardiovascular toxin in CKD-MBD.
    Moe SM
    Bone; 2017 Jul; 100():94-99. PubMed ID: 27576942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular calcification in CKD-MBD: Roles for phosphate, FGF23, and Klotho.
    Yamada S; Giachelli CM
    Bone; 2017 Jul; 100():87-93. PubMed ID: 27847254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The activin receptor is stimulated in the skeleton, vasculature, heart, and kidney during chronic kidney disease.
    Williams MJ; Sugatani T; Agapova OA; Fang Y; Gaut JP; Faugere MC; Malluche HH; Hruska KA
    Kidney Int; 2018 Jan; 93(1):147-158. PubMed ID: 28843411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metformin prevents the development of severe chronic kidney disease and its associated mineral and bone disorder.
    Neven E; Vervaet B; Brand K; Gottwald-Hostalek U; Opdebeeck B; De Maré A; Verhulst A; Lalau JD; Kamel S; De Broe ME; D'Haese PC
    Kidney Int; 2018 Jul; 94(1):102-113. PubMed ID: 29716795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanistic insights into CKD-MBD-related vascular calcification and its clinical implications.
    Kaur R; Singh R
    Life Sci; 2022 Dec; 311(Pt B):121148. PubMed ID: 36336124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early chronic kidney disease-mineral bone disorder stimulates vascular calcification.
    Fang Y; Ginsberg C; Sugatani T; Monier-Faugere MC; Malluche H; Hruska KA
    Kidney Int; 2014 Jan; 85(1):142-50. PubMed ID: 23884339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mineral metabolism and cardiovascular disease in CKD.
    Fujii H; Joki N
    Clin Exp Nephrol; 2017 Mar; 21(Suppl 1):53-63. PubMed ID: 28062938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contribution of Gut Microbiota-Derived Uremic Toxins to the Cardiovascular System Mineralization.
    Filipska I; Winiarska A; Knysak M; Stompór T
    Toxins (Basel); 2021 Apr; 13(4):. PubMed ID: 33920096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Vascular Calcification - Pathological Mechanism and Clinical Application - . Vascular calcification in chronic kidney disease-mineral and bone disorder (CKD-MBD)].
    Omata M; Fukagawa M; Kakuta T
    Clin Calcium; 2015 May; 25(5):645-53. PubMed ID: 25926567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The chronic kidney disease - Mineral bone disorder (CKD-MBD): Advances in pathophysiology.
    Hruska KA; Sugatani T; Agapova O; Fang Y
    Bone; 2017 Jul; 100():80-86. PubMed ID: 28119179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Klotho-FGF23, Cardiovascular Disease, and Vascular Calcification: Black or White?
    Cianciolo G; Galassi A; Capelli I; Schillaci R; La Manna G; Cozzolino M
    Curr Vasc Pharmacol; 2018 Jan; 16(2):143-156. PubMed ID: 28294047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A feline-focused review of chronic kidney disease-mineral and bone disorders - Part 2: Pathophysiology of calcium disorder and extraosseous calcification.
    Tang PK; Geddes RF; Jepson RE; Elliott J
    Vet J; 2021 Sep; 275():105718. PubMed ID: 34329743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular risk in chronic kidney disease (CKD): the CKD-mineral bone disorder (CKD-MBD).
    Hruska KA; Choi ET; Memon I; Davis TK; Mathew S
    Pediatr Nephrol; 2010 Apr; 25(4):769-78. PubMed ID: 19898875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mineral bone disorders in chronic kidney disease.
    Hou YC; Lu CL; Lu KC
    Nephrology (Carlton); 2018 Oct; 23 Suppl 4():88-94. PubMed ID: 30298663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality.
    Shalhoub V; Shatzen EM; Ward SC; Davis J; Stevens J; Bi V; Renshaw L; Hawkins N; Wang W; Chen C; Tsai MM; Cattley RC; Wronski TJ; Xia X; Li X; Henley C; Eschenberg M; Richards WG
    J Clin Invest; 2012 Jul; 122(7):2543-53. PubMed ID: 22728934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular calcification in chronic kidney disease: role of disordered mineral metabolism.
    Palit S; Kendrick J
    Curr Pharm Des; 2014; 20(37):5829-33. PubMed ID: 24533939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uremic serum-induced calcification of human aortic smooth muscle cells is a regulated process involving Klotho and RUNX2.
    Patidar A; Singh DK; Thakur S; Farrington K; Baydoun AR
    Biosci Rep; 2019 Oct; 39(10):. PubMed ID: 31519772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between soluble klotho and chronic kidney disease-mineral and bone disorder in chronic kidney disease: a meta-analysis.
    Fan Z; Wei X; Zhu X; Yang K; Tian L; Du Y; Yang L
    Sci Rep; 2024 Feb; 14(1):4477. PubMed ID: 38396063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mineral and Bone Disorder and Its Association with Cardiovascular Parameters in Chinese Patients with Chronic Kidney Disease.
    Zhou C; Wang F; Wang JW; Zhang LX; Zhao MH
    Chin Med J (Engl); 2016 Oct; 129(19):2275-80. PubMed ID: 27647184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The WNT/β-catenin system in chronic kidney disease-mineral bone disorder syndrome.
    Zhang L; Adu IK; Zhang H; Wang J
    Int Urol Nephrol; 2023 Oct; 55(10):2527-2538. PubMed ID: 36964322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.